Endocrinology, Vol 115, 2123-2132, Copyright © 1984 by Endocrine Society

ARTICLES

Effect of actinomycin D on iodide transport in FRTL-5 thyroid cells

C Marcocci, JL Cohen and EF Grollman

TSH-induced I- uptake in FRTL-5 thyroid cells requires new protein synthesis. During the induction of I- uptake, which takes nearly 60 h to reach its maximum, two waves of protein synthesis can be identified: one during the first 8 h and another after 24-30 h, each involving different proteins. Cycloheximide (CH) added during the first 10 h of a 48-h incubation with TSH completely inhibits the induction of I- uptake; 58% inhibition is observed with CH added at 24 h; no inhibition is observed when CH is added 36 h after TSH. Like CH, actinomycin D (ActD), added at the beginning of the 48-h period, inhibits TSH induction of I- uptake; partial inhibition (83%, 72%, and 28%) is observed when ActD is added at 1, 5, and 10 h, respectively. Treatment with ActD at 24 h (ActD-treated cells), however, paradoxically increases I- uptake (1.8- to 3.5-fold over the control value). The characteristics of I- uptake in ActD-treated cells are the same as those in untreated cells; both are Na+ dependent and can be inhibited in a comparable manner by anions. Kinetic measurements of I- transport indicate that ActD increases the rate of I- influx (2-fold or greater increase in maximum velocity without a significant change in Km), with only minor changes in I- release. Enhanced I- uptake in ActD-treated cells is inhibited by the simultaneous (24-h) administration of CH, indicating that protein synthesis is required for the late ActD effect. Despite an overall 2-fold decrease in protein synthesis in cells treated with ActD at 24 h, the synthesis of individual proteins maximally induced by TSH during the first 8 h is increased, whereas that of some proteins maximally synthesized after 24-30 h is markedly reduced. The present data indicate that TSH-induced I- uptake in FRTL-5 cells involves a regulatory action of TSH that operates at the mRNA level.

This article has been cited by other articles:

				O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S. Ginter, and N. Carrasco The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance Endocr. Rev., February 1, 2003; 24(1): 48 - 77. [Abstract] [Full Text] [PDF]

				U. Haberkorn, M. Henze, A. Altmann, S. Jiang, I. Morr, M. Mahmut, P. Peschke, W. Kübler, J. Debus, and M. Eisenhut Transfer of the Human NaI Symporter Gene Enhances Iodide Uptake in Hepatoma Cells J. Nucl. Med., February 1, 2001; 42(2): 317 - 325. [Abstract] [Full Text]

				A. E. Pekary, J. M. Hershman, and L. Berg Tumor Necrosis Factor, Ceramide, Transforming Growth Factor-{beta}1, and Aging Reduce Na+/I- Symporter Messenger Ribonucleic Acid Levels in FRTL-5 Cells Endocrinology, February 1, 1998; 139(2): 703 - 712. [Abstract] [Full Text] [PDF]

				T. Kogai, T. Endo, T. Saito, A. Miyazaki, A. Kawaguchi, and T. Onaya Regulation by Thyroid-Stimulating Hormone of Sodium/Iodide Symporter Gene Expression and Protein Levels in FRTL-5 Cells Endocrinology, June 1, 1997; 138(6): 2227 - 2232. [Abstract] [Full Text] [PDF]

				C. Riedel, O. Levy, and N. Carrasco Post-transcriptional Regulation of the Sodium/Iodide Symporter by Thyrotropin J. Biol. Chem., June 8, 2001; 276(24): 21458 - 21463. [Abstract] [Full Text] [PDF]